NANOFH Stock Overview
Engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nanoform Finland Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.09 |
| 52 Week High | €2.71 |
| 52 Week Low | €0.95 |
| Beta | 0.73 |
| 1 Month Change | -6.97% |
| 3 Month Change | -11.77% |
| 1 Year Change | -57.01% |
| 3 Year Change | -74.91% |
| 5 Year Change | n/a |
| Change since IPO | -78.34% |
Recent News & Updates
Recent updates
We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth
Nov 07
We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate
Apr 28We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely
Nov 04Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth
Jan 25What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition
Dec 21Shareholder Returns
| NANOFH | FI Life Sciences | FI Market | |
|---|---|---|---|
| 7D | 0.4% | 0.5% | -1.7% |
| 1Y | -57.0% | -25.2% | -7.7% |
Return vs Industry: NANOFH underperformed the Finnish Life Sciences industry which returned -25.2% over the past year.
Return vs Market: NANOFH underperformed the Finnish Market which returned -7.7% over the past year.
Price Volatility
| NANOFH volatility | |
|---|---|
| NANOFH Average Weekly Movement | 7.8% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in FI Market | 9.6% |
| 10% least volatile stocks in FI Market | 3.6% |
Stable Share Price: NANOFH's share price has been volatile over the past 3 months compared to the Finnish market.
Volatility Over Time: NANOFH's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Finnish stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 181 | Edward Haeggstrom | www.nanoform.com |
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and flexible dosage forms of nanoformed drug substances. It also offers STARMAP, an online platform to pick winners among candidate molecules for CESS powered nanoforming.
Nanoform Finland Oyj Fundamentals Summary
| NANOFH fundamental statistics | |
|---|---|
| Market cap | €93.57m |
| Earnings (TTM) | -€23.43m |
| Revenue (TTM) | €3.66m |
25.5x
P/S Ratio-4.0x
P/E RatioIs NANOFH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOFH income statement (TTM) | |
|---|---|
| Revenue | €3.66m |
| Cost of Revenue | €551.98k |
| Gross Profit | €3.11m |
| Other Expenses | €26.54m |
| Earnings | -€23.43m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 20, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 84.93% |
| Net Profit Margin | -639.69% |
| Debt/Equity Ratio | 0% |
How did NANOFH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 01:16 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanoform Finland Oyj is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Sami Sarkamies | Danske Bank |
| Christian Glennie | Stifel, Equities Research |